Navigation Links
Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009
Date:3/16/2009

Announces that Approximately 89.3 Percent of Outstanding Indevus Shares Have Been Accepted for Purchase

CHADDS FORD, Pa., March 16 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that, as of 5:00 p.m., New York City time, on March 13, 2009, approximately 71,008,964 shares (including shares delivered through notices of guaranteed delivery) were validly tendered and accepted for purchase in the tender offer by its wholly owned subsidiary, BTB Purchaser Inc., representing approximately 89.3% of the issued and outstanding shares of Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV).

Endo has extended the subsequent offering period for all of the outstanding shares of Indevus common stock until 5:00 p.m. New York City time on Wednesday, March 18, 2009. Endo and BTB do not intend to further extend the subsequent offering period, and expect to close the merger of Indevus and BTB following the expiration of the subsequent offering period.

During the extension of the subsequent offering period, BTB will accept for payment and promptly pay for Indevus shares as they are validly tendered each day. Stockholders who tender shares during such period will receive the same $4.50 per Indevus share in cash and the non-transferable contractual right to receive up to an additional $3.00 per Indevus share in cash payable upon achievement of certain regulatory and sales milestones as was paid to Indevus stockholders who previously tendered shares into the offer.

Procedures for tendering shares during this extension of the subsequent offering period shall be the same as during the subsequent offering period, including that shares may be delivered by the same guaranteed delivery procedure that was applicable during the initial offering period. Pursuant to Rule 14d-7(a)(2) under the Securities Exchange Act of 1934, as amended, shares tendered during the subsequent offering period may not be withdrawn.

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.

Important Information

This press release is neither an offer to purchase nor a solicitation of an offer to sell securities. Endo Pharmaceuticals Holdings Inc. ("Endo") has filed a tender offer statement on Schedule TO with the Securities and Exchange Commission, and Indevus Pharmaceuticals, Inc. ("Indevus") has filed a solicitation/recommendation statement with respect to the tender offer. Investors and Indevus shareholders are strongly advised to read the tender offer statement (including the offer to purchase, letter of transmittal and other offer documents) and the related solicitation/recommendation statement because they contain important information. The offer to purchase, the related letter of transmittal and certain other offer documents, as well as the solicitation/recommendation statement, are available at no charge on the Securities and Exchange Commission's website at www.sec.gov. In addition, copies of these documents and other filings containing information about Indevus and the transaction can be obtained by all Indevus stockholders, without charge, by directing a request to Indevus Pharmaceuticals, Inc., Attention: General Counsel, 33 Hayden Avenue, Lexington, Massachusetts 02421-7966, by telephone at (781) 861-8444 or on Indevus' website, www.indevus.com.


'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
2. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
3. VIA Pharmaceuticals Secures Financing Up to $10.0 Million
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
5. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
6. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
7. Onyx Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
8. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
9. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
10. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
11. AcelRx Pharmaceuticals Hires Mark Evashenk as Vice President of Clinical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... BILLERICA, Massachusetts , 30. November 2016 ... und Technologieunternehmen, hat heute die Unterzeichnung einer ... gegeben. Diesen zufolge wird Evotec AG Screeningleistungen ... und shRNA-Bibliotheken bereitstellen. Der Zugriff auf diese ... Bereich Screening eröffnet einen schnelleren Weg zur ...
(Date:11/30/2016)... ... November 30, 2016 , ... SSCI, the established leader in small-molecule cocrystal ... the latest FDA guidance on pharmaceutical cocrystals as drug substance . The ... , The event follows the successful November 15th event that took place in ...
(Date:11/30/2016)... ... November 30, 2016 , ... On 28 November 2016, the International Union ... nihonium (Nh), moscovium (Mc), tennessine (Ts), and oganesson (Og), respectively for element 113, ... earlier proposed by the discoverers have been approved by the IUPAC Bureau. The IUPAC ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... groundbreaking venture founded by Arianna Huffington, as part of the Thrive Global pop-up ... Explorer Kit, enabling purchasers to explore the microorganisms in their gut, collectively known ...
Breaking Biology Technology:
(Date:11/19/2016)... 2016 Securus Technologies, a leading provider of ... investigation, corrections and monitoring, announced today that it has ... have an independent technology judge determine who has the ... tech/sophisticated telephone calling platform, and the best customer service. ... most of what we do – which clearly is ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
Breaking Biology News(10 mins):